NervGen Pharma (NGENF) Stock Price, News & Analysis

Company Overview

NervGen Pharma Inc. is a clinical‐stage biotechnology company focused on developing novel therapies for injuries and diseases of the nervous system. The company’s chief development program, NVG-291, is a small‐molecule modulator of the protein tyrosine phosphatase receptor sigma (PTPσ), designed to promote nerve repair and functional recovery following central nervous system (CNS) injury. By targeting the molecular pathways that inhibit axon regeneration, NervGen aims to address high‐unmet‐need conditions such as spinal cord injury, multiple sclerosis and stroke.

NVG-291 has demonstrated proof‐of‐concept in preclinical models of CNS injury, where treatment resulted in enhanced remyelination and improved motor function. The company has advanced NVG-291 through toxicology studies and initiated a Phase 1 clinical trial in healthy volunteers to evaluate safety and pharmacokinetics. An open‐label, multi‐center Phase 1b/2 trial in patients with acute spinal cord injury is underway, with preliminary results anticipated to guide dose selection and inform future pivotal studies.

Founded in 2013 and headquartered in Richmond, British Columbia, NervGen holds an extensive intellectual property portfolio covering its PTPσ‐targeting compounds and methods of use. The company maintains operations in Canada and engagements with research centers in the United States to support its clinical programs. Under the leadership of CEO Ridgely Fisk Green, NervGen has secured strategic partnerships and funding to advance its pipeline toward regulatory milestones and potential out‐licensing or commercialization opportunities.

Key Stats

• Today's Range: $2.65 to $2.72
• 50-Day Range: $1.99 to $3.03
• 52-Week Range: $1.46 to $5.10
• Volume: 65,378 shs
• Average Volume: 127,243 shs
• Market Capitalization: $166.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

NGENF Stock Analysis - Frequently Asked Questions

How have NGENF shares performed this year?

NervGen Pharma's stock was trading at $2.18 at the beginning of the year. Since then, NGENF stock has increased by 22.7% and is now trading at $2.6740.

How do I buy shares of NervGen Pharma?

Shares of NGENF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/17/2025
• Next Earnings (Estimated): 11/13/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NGENF
• CIK: N/A
• Web: N/A
• Phone: (778) 731-1711
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.14%
• Return on Assets: -56.59%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 11.21
• Quick Ratio: 11.21

Sales & Book Value

• Annual Sales: $150 thousand
• Price / Sales: 1,115.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 61,770,000
• Free Float: N/A
• Market Cap: $167.40 million
• Optionable: Not Optionable
• Beta: N/A